Press Release: Mergers: Commission clears Teva’s proposed acquisition of Barr subject to conditions

The European Commission approved under the EU Merger Regulation the proposed acquisition of Barr Pharmaceuticals of the US by Teva Pharmaceutical Industries of Israel. Both companies produce generic medicines. To remedy the Commission's competition concerns in the field of cancer drugs and prescription vitamin products on a number of national markets, Teva made the commitment to divest fifteen cancer drugs in the Czech Republic, Hungary, Poland, the Slovak Republic and Slovenia, as well as two other drugs in Poland. In the light of these commitments, the Commission concluded that the proposed transaction would not cause competition concerns in the European Economic Area (EEA) or any substantial part of it.